Clinical TrialMay 29, 2026, 08:01 AM
Rhythm Pharma to Present 7 Clinical Data Abstracts at ENDO 2026
AI Summary
Rhythm Pharmaceuticals announced that seven presentations, including four late-breaking abstracts, have been accepted for The Endocrine Society's Annual Meeting (ENDO 2026). These presentations will feature updated Phase 2 results for setmelanotide in Prader-Willi syndrome, data on bivamelagon for acquired hypothalamic obesity, and long-term efficacy and Phase 3 results for setmelanotide in acquired hypothalamic obesity. Additionally, real-world evidence for setmelanotide in Bardet-Biedl syndrome will be presented, and Dr. Ashley Shoemaker will join the company as a medical director.
Key Highlights
- Rhythm Pharmaceuticals to present seven abstracts, including four late-breaking, at ENDO 2026.
- Updated Phase 2 results for setmelanotide in Prader-Willi syndrome from 17 of 18 patients after six months.
- Data on bivamelagon for weight reduction in acquired hypothalamic obesity after 1 year of treatment.
- Long-term efficacy data (2.5 years) for setmelanotide in acquired hypothalamic obesity from Phase 2 trial.
- Phase 3 data for setmelanotide in acquired hypothalamic obesity, including patients with prior bariatric surgery.
- Phase 3 data for setmelanotide in acquired hypothalamic obesity, focusing on weight category improvement.
- Two late-breaking real-world evidence posters for setmelanotide in Bardet-Biedl syndrome.
- Dr. Ashley Shoemaker to join Rhythm as Medical Director effective June 1, 2026.
Price Impact
More from RYTM